DFDA

Docetaxel

Treatment for Prostate Cancer

Typical Dosage: 75 mg/m² IV every 3 weeks (with prednisone)

Effectiveness
70%
Safety Score
25%
Clinical Trials
509
Participants
50K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
75 mg/m² IV every 3 weeks (with prednisone)
Time to Effect
1-2 months (symptom improvement)
Treatment Duration
4-7 months (6-10 cycles)
Evidence Quality
HIGH
Number Needed to Treat (NNT)
12(Treat 12 patients to see 1 additional successful outcome)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$20,000
Monitoring:$4,000
Side Effect Mgmt:$8,000
Total Annual:$32,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$60,000/QALY
QALYs Gained
0.7
Outcome-Based Costs
Cost per Responder
$71,111
Comparison vs ADT alone
Cost Difference
+$26,000/year
More expensive
QALY Difference
+0.70 QALYs
Better outcomes
Dominance
No dominance
Docetaxel Outcomes

for Prostate Cancer

Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+45%
Common Side Effects
Neutropenia
+75%
Fatigue
+65%
Alopecia
+75%
Peripheral neuropathy
+35%
Fluid retention/edema
+35%
Nausea/Vomiting
+35%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for Docetaxel in Prostate Cancer

M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

NCT04633252RECRUITINGPHASE1, PHASE2
View Study
86 participants
INTERVENTIONAL
Bethesda, United States
Started: Feb 23, 2021
Completed Clinical Trials
10 completed trials for Docetaxel in Prostate Cancer

Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer

NCT01796028COMPLETEDPHASE2
View Study
100 participants
INTERVENTIONAL
Nice, France
Started: Jan 1, 2013

Docetaxel in the Treatment of Hormone Refractory Prostate Cancer

NCT00280098COMPLETEDPHASE4
View Study
30 participants
INTERVENTIONAL
Prague, Czechia
Started: Jan 1, 2006

Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]

NCT00268710COMPLETEDPHASE2
View Study
INTERVENTIONAL
Started: Feb 1, 2004

CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)

NCT01206036COMPLETEDPHASE1, PHASE2
View Study
19 participants
INTERVENTIONAL
Essen, Germany +1 more
Started: Jul 1, 2010

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

NCT00313781COMPLETEDPHASE2
View Study
204 participants
INTERVENTIONAL
Los Angeles, United States +17 more
Started: May 1, 2006

PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone

NCT00291005COMPLETEDPHASE2
View Study
42 participants
INTERVENTIONAL
Tokyo, Japan
Started: Aug 1, 2004

Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer

NCT00137436COMPLETEDPHASE1, PHASE2
View Study
93 participants
INTERVENTIONAL
Harvey, United States +23 more
Started: Oct 1, 2005

Ketoconazole Plus Docetaxel to Treat Prostate Cancer

NCT00032825COMPLETEDPHASE1
View Study
674 participants
INTERVENTIONAL
Bethesda, United States
Started: Mar 19, 2002

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

NCT01683994COMPLETEDPHASE1, PHASE2
View Study
49 participants
INTERVENTIONAL
Bethesda, United States
Started: Sep 7, 2012

Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation

NCT00186420COMPLETEDPHASE2
View Study
13 participants
INTERVENTIONAL
Stanford, United States
Started: Jul 1, 2003
Showing 20 of 515 total trials